Psychedelic Mental Health Access Alliance

The Psychedelic Mental Health Access Alliance (PMHA Alliance) works to expand access to psychedelic-assisted therapy (PAT) for people most impacted by trauma, poverty, and unmet mental health needs—especially individuals and communities that have historically had the least access to emerging and breakthrough mental health treatments.

As psychedelic-assisted therapies move closer to mainstream medical adoption, PMHA Alliance exists to ensure that access is not limited to those with financial privilege or proximity to elite care settings. Our work is grounded in the belief that if psychedelic-assisted therapy is to fulfill its promise as a transformative mental health intervention, it must be responsibly integrated into public systems and designed to meet the needs of those most often excluded from innovation.

Our Focus: Publicly Funded, Real-World Care Models

PMHA Alliance focuses specifically on how publicly funded psychedelic-assisted therapy is delivered in real-world settings. Rather than operating solely in controlled or boutique environments, we work at the intersection of public mental health systems, Medicaid policy, community-based care, and clinical practice.

By developing and supporting pilot programs that operate within public and safety-net systems, PMHA Alliance generates practical, implementation-focused evidence. This evidence is designed to support policymakers, insurers, and state agencies as they evaluate how psychedelic-assisted therapy can be responsibly covered, regulated, and delivered through public systems.

Our work prioritizes feasibility, scalability, and accountability—recognizing that access at scale requires more than clinical efficacy alone. It requires viable care models, trained workforces, supportive infrastructure, and alignment with existing health systems.

Why an Alliance

PMHA Alliance operates as an alliance because no single sector can solve the access challenge alone. Expanding access to psychedelic-assisted therapy requires coordination across healthcare delivery systems, policy and regulation, workforce training, research, community engagement, and lived experience.

We bring together legislators, advocacy organizations, community-based organizations, health equity leaders, clinicians, researchers, and people with lived experience to collaboratively design and support publicly funded PAT care models. Our role is to serve as a bridge—facilitating shared learning, aligning incentives, and translating insights across sectors that do not always work in close coordination.

By fostering collaboration rather than competition, PMHA Alliance helps ensure that emerging psychedelic care models are grounded in community needs, informed by real-world constraints, and built to last.

Community-Informed and Access-Driven

Community voice and lived experience are central to PMHA Alliance’s approach. We work alongside community-based organizations and local stakeholders to ensure that care models reflect cultural context, address barriers beyond cost alone, and incorporate wraparound supports that are often essential for meaningful outcomes.

Our access-driven approach recognizes that barriers to care include not only affordability, but also trust, workforce representation, geographic availability, integration support, and alignment with social determinants of health. By addressing these factors upstream, PMHA Alliance aims to support care models that are not only clinically effective, but also accessible, ethical, and responsive to real community needs.

Building Toward Long-Term Systems Change

PMHA Alliance is focused on long-term systems change rather than short-term wins. Through pilot studies, workforce development efforts, and collaborative data frameworks, we are laying the groundwork for psychedelic-assisted therapy to be integrated into public mental health systems in ways that are sustainable and equitable.

Our leadership team and collaborators span the United States and bring deep experience in public health, Medicaid policy, community-engaged research, clinical care, and psychedelic-assisted therapy implementation. Together, we are working to ensure that as psychedelic-assisted therapy enters the medical mainstream, access is expanded thoughtfully, responsibly, and in service of the public good.